Tumor-promoting function and regulatory landscape of PD-L2 in B-cell lymphoma

Sumito Shingaki^#¹, Junji Koya^#¹, Mitsuhiro Yuasa^#^{1

2}, Yuki Saito^{1

3}, Mariko Tabata^{1

4}, Marni B McClure¹, Seishi Ogawa^{5

6

7}, Kotoe Katayama⁸, Yosuke Togashi⁹, Seiya Imoto¹⁰, Yasunori Kogure¹, Keisuke Kataoka^{11

12}

Affiliations

¹ Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
² Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
³ Department of Gastroenterology, Keio University School of Medicine, Tokyo, Japan.
⁴ Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
⁵ Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
⁶ Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan.
⁷ Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden.
⁸ Laboratory of Sequence Analysis, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
⁹ Department of Tumor Microenvironment, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
¹⁰ Division of Health Medical Intelligence, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
¹¹ Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan. kkataoka-tky@umin.ac.jp.
¹² Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan. kkataoka-tky@umin.ac.jp.

^# Contributed equally.

Sumito Shingaki et al. Leukemia. 2023 Feb.

. 2023 Feb;37(2):492-496.

doi: 10.1038/s41375-022-01772-1. Epub 2022 Dec 15.

¹ Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan.
² Department of Pathology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
³ Department of Gastroenterology, Keio University School of Medicine, Tokyo, Japan.
⁴ Department of Urology, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan.
⁵ Department of Pathology and Tumor Biology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
⁶ Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan.
⁷ Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden.
⁸ Laboratory of Sequence Analysis, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
⁹ Department of Tumor Microenvironment, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama University, Okayama, Japan.
¹⁰ Division of Health Medical Intelligence, Human Genome Center, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
¹¹ Division of Molecular Oncology, National Cancer Center Research Institute, Tokyo, Japan. kkataoka-tky@umin.ac.jp.
¹² Division of Hematology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan. kkataoka-tky@umin.ac.jp.

^# Contributed equally.

No abstract available

References

1. Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. Sci Adv. 2020;6:eabd2712.
1. Chang K, Creighton CJ, Davis C, Donehower L, Drummond J, Wheeler D, et al. The cancer genome atlas pan-cancer analysis project. Nat Genet. 2013;45:1113–20. - DOI
1. Schmitz R, Wright GW, Huang DW, Johnson CA, Phelan JD, Wang JQ, et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N Engl J Med. 2018;378:1396–407. - DOI
1. Kataoka K, Miyoshi H, Sakata S, Dobashi A, Couronne L, Kogure Y, et al. Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. Leukemia. 2019;33:1687–99. - DOI
1. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell. 2015;160:48–61. - DOI